Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia

Journal of Clinical Rheumatology

Volumn 13, Issue 2, 2007, Pages 94-95

  Finger, Eduardo ^a   Scheinberg, Morton ^a  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Adverse events; Hypergammaglobulinemia; Rituximab; Serum sickness

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; HYDROCORTISONE; RITUXIMAB;

ADULT; ARTHRITIS; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG ERUPTION; DRUG FEVER; ERYTHEMA; FEMALE; HUMAN; HYPERGAMMAGLOBULINEMIA; MALAISE; PRIORITY JOURNAL; PURPURA; SERUM SICKNESS; SHIVERING; TREATMENT INDICATION; TREATMENT OUTCOME; URTICARIA; WHEEZING;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; HYPERGAMMAGLOBULINEMIA; MIDDLE AGED; SERUM SICKNESS; TREATMENT OUTCOME;

EID: 34247156626     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000262585.18582.1e     Document Type: Article

References (13)

1. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005;72:250-256.
2. Eisenberg R. Update on rituximab. Ann Rheum Dis. 2005;64(Suppl 4):iv55-iv57.
3. Malaviya AN, Kaushik P, Budhiraja S, et al. Hypergammaglobulinemic purpura of Waldenstrom: report of 3 cases with a short review. Clin Exp Rheumatol. 2000;18:518-522.
4. Scheinberg M, Hamerschlak N, Kutner JM, et al. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004). Clin Exp Rheumatol. 2006;24:65-69.
5. D'Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum. 2001;44:1717-1718.
6. Herishanu Y. Rituximab-induced serum sickness. Am J Hematol. 2002;70:329.
7. Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol. 2003;14:1792.
8. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64:913-920.
9. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum. 2005;52:2740-2750.
10. Catuogno M, Rezai S, Priori R, et al. Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia. Rheumatology (Oxford). 2005;44:406.
11. Bennett C, Rogers Z, Kinnamon D, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107:2639-2642.
12. Doan T, Massarotti E. Rituximab. Drugs Today (Barc). 2005;41:785-797.
13. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26(5 Suppl 14):66-73.